---
title: The difference between absolute risks and relative risks
author: Steve Simon
date: 2005-07-15
category:
- Blog post
tags:
- Measuring benefit/risk
output: html_document
---
There are two general ways to compare a treatment and a control group,
relative comparisons and absolute comparisons. For a relative
comparison, the basic computation is division. When the ratio A/B is
larger than one, that implies that A is superior to B. For an absolute
comparison, the basic computation is subtraction. When the difference
A-B is greater than zero, that implies that A is superior to B. The
distinction between relative and absolute is not the only important
distinction, but it does represent a fundamental property of measures of
effectiveness. Relative measures represent measures where the
fundamental calculation is a division and absolute measures represent
measures where the fundamental calculation is a subtraction.

Surprisingly, the choice between division and subtraction is critical.
Relative and absolute comparisons often paint quite a different picture.
There is substantial consensus in the evidence-based medicine community
that relative measures of risk (such as an odds ratio or relative risk)
tend to be misperceived by clinicians and patients and that they get a
better sense of the value of a treatment when they receive information
presented on an absolute scale (such as an absolute risk reduction or a
number needed to treat). The general trend is that interventions appear
more attractive when presented in relative terms, but less attractive
when presented in absolute terms. The effect is strongest when the
events being compared are relatively rare.

**Further reading**

-   **Completeness of reporting trial results: effect on physicians\'
    willingness to prescribe.** Bobbio M, Demichelis B, Giustetto G.
    Lancet 1994: 343(8907); 1209-11.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7909875&dopt=Abstract)
-   **General practice registrar responses to the use of different risk
    communication tools in simulated consultations: a focus group
    study.** Edwards A. British Medical Journal 1999: 319(7212);
    749-752.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10488001&dopt=Abstract)
    [\[Abstract\]](http://bmj.bmjjournals.com/cgi/content/abstract/319/7212/749)
    [\[Full
    text\]](http://bmj.bmjjournals.com/cgi/content/full/319/7212/749)
    [\[PDF\]](http://bmj.bmjjournals.com/cgi/reprint/319/7212/749.pdf)
-   **Explaining risks: turning numerical data into meaningful
    pictures.** Edwards A, Elwyn G, Mulley A. Bmj 2002: 324(7341);
    827-30.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11934777&dopt=Abstract)
    [\[Full text\]](http://bmj.com/cgi/content/full/324/7341/827)
    [\[PDF\]](http://bmj.com/cgi/reprint/324/7341/827.pdf)
-   **evidence-based purchasing: understanding results of clinical
    trials and systematic reviews.** Fahey T, Griffiths S, Peters TJ.
    British Medical Journal 1995: 311(7012); 1056-9; discussion 1059-60.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7580661&dopt=Abstract)
    [\[Abstract\]](http://bmj.com/cgi/content/abstract/311/7012/1056)
    [\[Full text\]](http://bmj.com/cgi/content/full/311/7012/1056)
-   **Absolutely relative: how research results are summarized can
    affect treatment decisions.** Forrow L, Taylor W, Arnold R. The
    American Journal of Medicine 1992: 92(2); 121-24.
-   **Communicating the benefits of chronic preventive therapy: does the
    format of efficacy data determine patients\' acceptance of
    treatment?** Hux J, Naylor C. Medical Decision Making 1995: 15(2);
    152-7.
-   **Absolute and relative truth in clinical trials.** Julian D. Lancet
    2002(June): 359(9321); 1945-1946.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12057577&dopt=Abstract)
    [\[Full
    text\]](http://www.thelancet.com/journals/lancet/article/PIIS0140673602087500/fulltext)
-   **Quality of life questionnaires: does statistically significant =
    clinically important?** Juniper EF. J Allergy Clin Immunol 1998:
    102(1); 16-7.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9679842&dopt=Abstract)
    [\[Full
    text\]](http://www2.us.elsevierhealth.com/scripts/om.dll/serve?retrieve=/pii/S0091674998002334&nav=full)
    [\[PDF\]](http://www2.us.elsevierhealth.com/scripts/om.dll/serve?action=get-media&id=a90088&trueID=pdf_90088&location=jai981021&type=pdf&name=x.pdf)
-   **An assessment of clinically useful measures of the consequences of
    treatment.** Laupacis A, Sackett D, Roberts R. New England Journal
    of Med 1988: 318(26); 1728-1733.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3374545&dopt=Abstract)
-   **Consider absolute risks in SIDS prevention.** Logan S, Bedford H,
    Elliman D. Arch Dis Child 2000: 83(5); 457.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11203153&dopt=Abstract)
    [\[Full
    text\]](http://adc.bmjjournals.com/cgi/content/full/83/5/456d)
    [\[PDF\]](http://adc.bmjjournals.com/cgi/reprint/83/5/456d.pdf)
-   **Who benefits from medical interventions?** Smith GD, Egger M. Bmj
    1994: 308(6921); 72-4.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8298415&dopt=Abstract)
    [\[Full text\]](http://bmj.com/cgi/content/full/308/6921/72)
-   **\"Absolute\" is inappropriate for quantitative risk estimation.**
    Tunstall-Pedoe H. BMJ 2000: 320(7236); 723-. [\[Full
    text\]](http://bmj.com/cgi/content/full/320/7236/723)

You can find an [earlier version](http://www.pmean.com/05/AbsoluteRisk.html) of this page on my [original website](http://www.pmean.com/original_site.html).
